<DOC>
	<DOCNO>NCT02680808</DOCNO>
	<brief_summary>Open label evaluation potential interaction F901318 cytochrome P450 3A4 use midazolam probe . Twenty healthy male subject participate</brief_summary>
	<brief_title>Evaluation Potential Cytochrome P450 3A4 Inhibition F901318 Using Oral Midazolam Probe</brief_title>
	<detailed_description>This open label study midazolam ( dose 2 mg orally , Day 1 ) follow midazolam ( 2 mg orally ) give dose intravenous F901318 4 mg/kg bid one day follow 2.5 mg/kg bid 7 dos ( Day 7 ) . Up twenty subject include two cohort undergo dose schedule midazolam F901318 undergo procedure . The first cohort consist 12 subject study two group six subject . If clearly difference midazolam kinetics detectable first second dos midazolam , first cohort , second cohort study . If clear difference , second cohort also study give final result . PK sample midazolam 1- 4-hydroxymidazolam plasma urine concentration continue include 24 hour dose midazolam occasion . PK sample F901318 continue first dose 24 hour ninth dose . A follow visit conduct 7 +/- 2 day discharge clinical unit follow completion blood sample follow second dose midazolam ninth dose F901318 .</detailed_description>
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>1 . Subjects males ethnic origin 18 45 year age weigh 60100 kg inclusive . 2 . Subjects must good health , determine medical history , physical examination , 12lead electrocardiogram ( ECG ) clinical laboratory evaluation ( congenital non haemolytic hyperbilirubinaemia acceptable ) . 3 . Subjects give write informed consent participate study abide study restriction . 4 . Subjects must ophthalmology assessment within normal limit screen . This include normal Meibomian gland function . 1 . Male subject willing use appropriate contraception study three month thereafter . 2 . Subjects receive prescribed systemic topical medication within 14 day dose administration unless opinion Investigator Medical Monitor medication interfere study procedure compromise safety . 3 . Subjects use nonprescribed systemic topical medication ( include herbal remedy ) within 7 day dose administration ( exception vitamin/mineral supplement paracetamol ) unless opinion Investigator Medical Monitor medication interfere study procedure compromise safety . 4 . Subjects receive medication , include St John 's Wort , know chronically alter drug absorption elimination process within 30 day dose administration unless opinion Investigator Medical Monitor medication interfere study procedure compromise safety . For least 2 week prior dose blood sample observation complete Day 15 +/ 2 , subject allow eat food drink beverage contain alcohol , grapefruit grapefruit juice , apple orange juice , vegetables mustard green family e.g . kale , broccoli , watercress , spring green , kohlrabi , Brussels sprout , mustard charbroiled meat .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>